Accueil/Actions/BCAB

BCAB

USD

BioAtla Inc. Common Stock

$0.673+0.023 (3.615%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$0.650

Haut

$0.678

Bas

$0.613

Volume

0.11M

Fondamentaux de l'Entreprise

Capitalisation Boursière

39.5M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.01M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.24Actuel $0.673Haut $2.525

Actualités Connexes

23 oct. 2025 · 12:00

GlobeNewswire

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

3 oct. 2025 · 13:00

GlobeNewswire

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its